Wang Weier, Fei Yanhong, Liu Jie, Yu Tunan, Tang Jianming, Wei Fangqiang
Department of Hepatobiliary and Pancreatic Surgery, Zhejiang Provincial People's Hospital, Hangzhou Medical College, Hangzhou, China.
Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.
ANZ J Surg. 2021 Jan;91(1-2):42-48. doi: 10.1111/ans.15948. Epub 2020 May 12.
The role of laparoscopic surgery (Lap) and robotic surgery (Rob) for radical resection of hilar cholangiocarcinoma (HC) is not clear. We summarized the safety and feasibility of Lap and Rob for HC.
A search of all HC studies in English published on PubMed up to April 2020 was conducted. References from retrieved articles were reviewed to broaden the search.
In total, 23 reports were enrolled: 15 involving Lap, seven using Rob and one study reporting a minimally invasive approach (Lap or Rob, not specified). A total of 205 cases of HC were documented (Lap/Rob/not specified, 99/101/5): 37 cases of Bismuth type-I (Lap/Rob, 17/20), 22 cases of Bismuth type-II (Lap/Rob, 15/7), 68 cases of type-III (Lap/Rob, 39/29) and 13 cases of type-IV (Lap/Rob, 9/4). The pooled prevalence of R0 resection was 80.1% (Lap/Rob, 85.9%/71.0%). The weighted mean for operative time, blood loss and post-operative hospital stay was 458.4 min (Lap/Rob, 423.3/660.8 min), 615.3 mL (Lap/Rob, 521.0/1188.5 mL) and 14.0 days (Lap/Rob, 14.0/13.7 days), respectively. The pooled prevalence of conversion to open surgery, post-operative complications, and perioperative mortality was 9.1% (Lap/Rob, 12.2%/3.8%), 47.2% (Lap/Rob, 38.4%/61.3%) and 3.0% (Lap/Rob, 4.0%/2.0%), respectively.
With innovations in technology and gradual accumulation of surgical experience, the feasibility and safety of performing Lap and Rob for HC will improve.
腹腔镜手术(Lap)和机器人手术(Rob)在肝门部胆管癌(HC)根治性切除中的作用尚不清楚。我们总结了Lap和Rob用于HC的安全性和可行性。
检索了截至2020年4月在PubMed上发表的所有英文HC研究。对检索到的文章的参考文献进行了审查以扩大搜索范围。
共纳入23篇报告:15篇涉及Lap,7篇使用Rob,1项研究报告了微创方法(Lap或Rob,未明确)。共记录了205例HC病例(Lap/Rob/未明确,99/101/5):37例Bismuth I型(Lap/Rob,17/20),22例Bismuth II型(Lap/Rob,15/7),68例III型(Lap/Rob,39/29)和13例IV型(Lap/Rob,9/4)。R0切除的合并患病率为80.1%(Lap/Rob,85.9%/71.0%)。手术时间、失血量和术后住院时间的加权平均值分别为458.4分钟(Lap/Rob,423.3/660.8分钟)、615.3毫升(Lap/Rob,521.0/1188.5毫升)和14.0天(Lap/Rob,14.0/13.7天)。转为开放手术、术后并发症和围手术期死亡率的合并患病率分别为9.1%(Lap/Rob,12.2%/3.8%)、47.2%(Lap/Rob,38.4%/61.3%)和3.0%(Lap/Rob,4.0%/2.0%)。
随着技术创新和手术经验的逐步积累,Lap和Rob用于HC的可行性和安全性将会提高。